ATE234112T1 - Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit - Google Patents

Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit

Info

Publication number: ATE234112T1
Authority: AT; Austria
Prior art keywords: glp; obesity; analogues; regulation; derivatives
Prior art date: 1996-11-05

Application number

AT97947357T

Other languages

English (en)

Inventor

Richard D Dimarchi

Suad Efendic

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-05

Filing date

1997-11-04

Publication date

2003-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26705788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE234112(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-04 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE234112T1 publication Critical patent/ATE234112T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 4
208000008589 Obesity Diseases 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1
230000002093 peripheral effect Effects 0.000 title 1
DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
-1 GLP-1 Chemical class 0.000 abstract 1
108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 1
102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Child & Adolescent Psychology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

AT97947357T 1996-11-05 1997-11-04 Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit ATE234112T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3021396P	1996-11-05	1996-11-05
US08/961,405 US6191102B1 (en)	1996-11-05	1997-10-30	Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
PCT/US1997/020114 WO1998019698A1 (en)	1996-11-05	1997-11-04	Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity

Publications (1)

Publication Number	Publication Date
ATE234112T1 true ATE234112T1 (de)	2003-03-15

Family

ID=26705788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97947357T ATE234112T1 (de)	1996-11-05	1997-11-04	Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit

Country Status (18)

Country	Link
US (4)	US6191102B1 (de)
EP (1)	EP0946191B1 (de)
CN (1)	CN1268391C (de)
AT (1)	ATE234112T1 (de)
AU (1)	AU734042B2 (de)
CA (1)	CA2271169C (de)
DE (1)	DE69719798T2 (de)
DK (1)	DK0946191T3 (de)
ES (1)	ES2194224T3 (de)
HU (1)	HUP0003314A3 (de)
IL (1)	IL129852A (de)
MY (1)	MY129220A (de)
NO (1)	NO992557L (de)
NZ (1)	NZ335995A (de)
PT (1)	PT946191E (de)
UA (1)	UA65549C2 (de)
WO (1)	WO1998019698A1 (de)
YU (1)	YU24199A (de)

Families Citing this family (314)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) *	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) *	1999-08-11	2005-03-01	Cedars-Sinai Medical Center	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) *	1996-11-12	2005-12-29	Novo Nordisk A/S	Verwendung von glp-1 peptiden
DE122007000044I2 (de)	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
WO1999014239A1 (de) *	1997-09-12	1999-03-25	Wolf Georg Forssmann	Zusammensetzung zur therapie von diabetes mellitus und fettsucht
MXPA00004670A (es)	1997-11-14	2003-07-14	Amylin Pharmaceuticals Inc	Compuestos agonistas de exendina novedosos.
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
US6998387B1 (en)	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) *	1998-03-19	1999-09-23	Bionebraska, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
BR9913284A (pt) *	1998-08-28	2001-05-15	Lilly Co Eli	Métodos para administrar peptìdeos insulinotrópicos
EP1666054A1 (de) *	1998-08-28	2006-06-07	Eli Lilly & Company	Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
US6720407B1 (en)	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
CZ295044B6 (cs) *	1998-12-07	2005-05-18	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1992641A3 (de)	1998-12-07	2009-07-29	Ipsen Pharma	GLP-1-Analoge
PL189664B1 (pl) *	1998-12-07	2005-09-30	Sod Conseils Rech Applic	Nowy analog GLP-1, kompozycja farmaceutyczna go zawierająca oraz zastosowanie nowego analogu GLP-1
US6605648B1 (en) *	1999-04-06	2003-08-12	Phillips Plastics Corporation	Sinterable structures and method
BR0010750A (pt) *	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
DK1808438T3 (da)	1999-06-29	2014-10-27	Mannkind Corp	Rensning og stabilisering af peptid og proteiner i lægemidler
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP1076066A1 (de)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6569901B2 (en) *	2000-01-28	2003-05-27	Novo Nordisk A/S	Alkynyl-substituted propionic acid derivatives, their preparation and use
EP2213743A1 (de)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albuminfusionsproteine
US20020061838A1 (en) *	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
IL147731A0 (en) *	2000-05-19	2002-08-14	Bionebraska Inc	Peptide pharmaceutical formulations
JP4716641B2 (ja)	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
CA2430934C (en)	2000-12-01	2011-06-21	Takeda Chemical Industries, Ltd.	A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
AU3938402A (en) *	2000-12-13	2002-06-24	Lilly Co Eli	Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1572871A4 (de) *	2001-04-20	2007-11-14	Sinai School Medicine	T1r3, ein neuer geschmacksrezeptor
US7803982B2 (en)	2001-04-20	2010-09-28	The Mount Sinai School Of Medicine Of New York University	T1R3 transgenic animals, cells and related methods
WO2002097038A2 (en) *	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
EP1572885A2 (de) *	2001-08-08	2005-09-14	Genzyme Corporation	Verfahren zur behandlung von diabetes und anderer blutzuckerstörungen
US20040143104A1 (en) *	2001-08-08	2004-07-22	Wadsworth Samuel C.	Methods of treating diabetes and other blood sugar disorders
AU2002322403A1 (en) *	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
EP1432430A4 (de) *	2001-08-28	2006-05-10	Lilly Co Eli	Vormischungen von glp-1 und basalinsulin
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
MXPA04003569A (es) *	2001-10-19	2004-07-23	Lilly Co Eli	Mezclas bifasicas de glp-1 e insulina.
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003059934A2 (en) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US8058233B2 (en) *	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
EP1474163A2 (de) *	2002-01-10	2004-11-10	Imperial College Innovations Limited	Veränderung des fütterungsverhaltens
PL209734B1 (pl) *	2002-02-20	2011-10-31	Emisphere Tech Inc	Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
DE60335608D1 (de) *	2002-02-27	2011-02-17	Pharmain Corp	Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
US20040018959A1 (en) *	2002-05-02	2004-01-29	Randall S. Hickle	System and methods of lipid removal from the body
US7374930B2 (en) *	2002-05-21	2008-05-20	Expression Genetics, Inc.	GLP-1 gene delivery for the treatment of type 2 diabetes
US7329798B2 (en) *	2002-06-28	2008-02-12	University Of Guelph	Harvest-inducible regulatory elements and methods of using same
WO2004005342A1 (en) *	2002-07-04	2004-01-15	Zealand Pharma A/S	Glp-1 and methods for treating diabetes
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BR0314996A (pt) *	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
AU2003283004A1 (en) *	2002-10-22	2004-05-13	Waratah Pharmaceuticals, Inc.	Treatment of diabetes
US7166575B2 (en) *	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7229966B2 (en) *	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) *	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
BR0316685A (pt) *	2002-12-17	2005-11-01	Nastech Pharm Co	Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
KR101198346B1 (ko) *	2003-04-08	2012-11-06	노보 노르디스크 에이/에스	크로마토그래피 고정상의 재생
WO2004089985A1 (en) *	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
EP1617888B1 (de)	2003-04-23	2019-06-12	Valeritas, Inc.	Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
EP2644206B1 (de)	2003-05-23	2019-04-03	Nektar Therapeutics	PEG-Derivative die zwei PEG Ketten enthalten
DK1641823T3 (da)	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1-analog fusionsproteiner
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US20050244810A1 (en) *	2003-09-29	2005-11-03	Egan Josephine M	Taste signaling in gastrointestinal cells
US20050107318A1 (en) *	2003-11-17	2005-05-19	Samuel Wadsworth	Methods of treating diabetes and other blood sugar disorders
EP2298337B1 (de) *	2003-12-09	2017-02-22	Novo Nordisk A/S	Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
JP2007536214A (ja)	2003-12-16	2007-12-13	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１類似体
EP1694278A4 (de)	2003-12-16	2009-08-12	Ipsen Pharma	Glp-1 pharmazeutische zusammensetzungen
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
AU2005203925A1 (en)	2004-01-08	2005-07-21	Theratechnologies Inc.	Glucagon-Like Peptide-1 analogs with long duration of action
WO2005072045A2 (en) *	2004-01-30	2005-08-11	Waratah Pharmaceuticals, Inc.	The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US20070135338A1 (en) *	2004-03-31	2007-06-14	Karyn O'neil	Human GLP-1 mimetibodies, compositions, methods and uses
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
HRP20060362A2 (en) *	2004-04-23	2007-03-31	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
US7687638B2 (en) *	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
EP1758575A1 (de) *	2004-06-11	2007-03-07	Novo Nordisk A/S	Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
WO2006014425A1 (en) *	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US20090305964A1 (en) *	2005-04-21	2009-12-10	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CA2608311C (en)	2005-05-13	2012-11-27	Eli Lilly And Company	Glp-1 pegylated compounds
BRPI0610089A2 (pt) *	2005-05-27	2008-12-09	Asubio Pharma Co Ltd	intensificador de resistÊncia À insulina
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
CN101258163B (zh)	2005-06-30	2013-08-21	益普生制药股份有限公司	Glp-1药物组合物
US20070016262A1 (en)	2005-07-13	2007-01-18	Betastim, Ltd.	Gi and pancreatic device for treating obesity and diabetes
US10022457B2 (en)	2005-08-05	2018-07-17	Gholam A. Peyman	Methods to regulate polarization and enhance function of cells
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
CA2913805A1 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
US8039432B2 (en) *	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20070149442A1 (en) *	2005-12-13	2007-06-28	Byron Rubin	Non-hygroscopic compositions of enterostatin
WO2007070563A2 (en) *	2005-12-13	2007-06-21	Harkness Pharmaceuticals, Inc.	Stable solid forms of enterostatin
EP1973558A4 (de) *	2005-12-13	2009-12-23	Harkness Pharmaceuticals Inc	Verfahren zur behandlung von adipositas mit enterostatin
EP2364735A3 (de)	2005-12-16	2012-04-11	Nektar Therapeutics	Verzweigte PEG-Kon jugate von GLP-1
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
CN101384623B (zh) *	2005-12-22	2013-07-24	常山凯捷健生物药物研发（河北）有限公司	白蛋白与治疗剂的预成型偶联物的制备方法
IN2015DN00888A (de)	2006-02-22	2015-07-10	Mannkind Corp
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR101361376B1 (ko)	2006-03-30	2014-02-10	발레리타스 인코포레이티드	복합-카트리지 유체 전달 장치
MX2008013168A (es) *	2006-04-13	2008-10-27	Sod Conseils Rech Applic	Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
PT2035451E (pt) *	2006-06-23	2010-06-09	Hoffmann La Roche	Síntese de péptidos insulinotrópicos
JP2009542813A (ja) *	2006-07-11	2009-12-03	ハルクネススプハルマセウティカルス，インコーポレイテッド	飽食因子を使用して肥満を治療する方法
CN101511868B (zh)	2006-07-24	2013-03-06	比奥雷克西斯制药公司	毒蜥外泌肽融合蛋白
EP2359808B1 (de)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotisches Verabreichungssystem mit Kolbenanordnung
US7839952B2 (en) *	2006-12-05	2010-11-23	Provigent Ltd	Data rate coordination in protected variable-rate links
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
RU2477286C2 (ru) *	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
AU2008214338A1 (en) *	2007-02-02	2008-08-14	Redpoint Bio Corporation	Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release
CA2677932A1 (en)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
WO2008133908A2 (en) *	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
US20110034373A1 (en) *	2007-08-03	2011-02-10	Eli Lilly And Company	Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
WO2009055742A2 (en) *	2007-10-24	2009-04-30	Mannkind Corporation	Delivery of active agents
JP2011500850A (ja) *	2007-10-24	2011-01-06	マンカインドコーポレイション	Ｇｌｐ−１による副作用を防止する方法
ES2509883T3 (es)	2007-10-30	2014-10-20	Indiana University Research And Technology Corporation	Antagonistas de glucagón
MX2010004298A (es) *	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
JP2011506442A (ja) *	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
EP2249853A4 (de)	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	Peptid-prodrugs auf esterbasis
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
US8450270B2 (en) *	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh) *	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) *	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
US8765669B2 (en)	2008-06-17	2014-07-01	Glytech, Inc.	Glycosylated GLP-1 peptide
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
ES2561208T3 (es) *	2008-09-12	2016-02-25	Novo Nordisk A/S	Método de acilación de un péptido o una proteína
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
CA2737461A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care, Inc.	Solute concentration measurement device and related methods
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5789515B2 (ja)	2008-12-19	2015-10-07	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン類似体
AU2009335715B2 (en)	2008-12-19	2016-09-15	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
PE20120332A1 (es)	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP1-analoge pharmazeutische Zusammensetzungen
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US8614185B2 (en)	2009-05-04	2013-12-24	Centocor Ortho Biotech Inc.	Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en)	2009-05-06	2010-11-11	Centocor Ortho Biotech Inc.	Melanocortin receptor binding conjugates
US20100286628A1 (en) *	2009-05-07	2010-11-11	Rainbow Medical Ltd	Gastric anchor
US8414559B2 (en) *	2009-05-07	2013-04-09	Rainbow Medical Ltd.	Gastroretentive duodenal pill
US20110066175A1 (en) *	2009-05-07	2011-03-17	Rainbow Medical Ltd.	Gastric anchor
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
EP2443146B1 (de)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Gip-rezeptor-aktive glucagon-verbindungen
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
US8926561B2 (en)	2009-07-30	2015-01-06	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
BR112012004335A8 (pt)	2009-09-02	2016-06-21	Merck Sharp & Dohme	Composto, composição farmacêutica, e, uso do composto.
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
KR20120101037A (ko)	2009-10-30	2012-09-12	오츠카 가가쿠 가부시키가이샤	항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
EP2460527A1 (de) *	2010-01-21	2012-06-06	Sanofi	Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
US8853212B2 (en)	2010-02-22	2014-10-07	Merck Sharp & Dohme Corp	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011123943A1 (en)	2010-04-09	2011-10-13	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CN107129538B (zh)	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
MX2012013001A (es) *	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
US8980929B2 (en)	2010-05-21	2015-03-17	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP5969469B2 (ja)	2010-06-16	2016-08-17	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
US9169310B2 (en) *	2010-06-24	2015-10-27	Zealand Pharma A/S	Glucagon analogues
EP2588126A4 (de)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	Amidbasierte glucagon-superfamilien-peptid-prodrugs
EP2585102B1 (de)	2010-06-24	2015-05-06	Indiana University Research and Technology Corporation	Auf amid basierende insulin-prodrugs
JP2013530993A (ja)	2010-07-02	2013-08-01	アンジオケムインコーポレーテッド	治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102643339B (zh) *	2011-02-21	2014-04-09	天津药物研究院	一种glp-1类似物、制备方法及其应用
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
KR20140043793A (ko)	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
US20130090285A1 (en) *	2011-06-27	2013-04-11	Phasebio Pharmaceuticals, Inc.	Methods of treatment with glp-1 receptor agonists
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UY34347A (es)	2011-09-26	2013-04-30	Novartis Ag	Proteínas de función dual para tratar trastornos metabólicos
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
CN104039344A (zh) *	2011-10-28	2014-09-10	法瑞斯生物技术有限公司	用于防止心脏缺血-再灌注损伤的多肽
US20140336118A1 (en) *	2011-10-28	2014-11-13	Pharis Biotec Gmbh	Polypeptide for the protection against heart ischemia-reperfusion injury
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
BR112014015156A2 (pt)	2011-12-20	2020-10-27	Indiana University Research And Technology Corporation	análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
BR112014014898A2 (pt)	2011-12-22	2020-10-27	Pfizer Inc.	processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2
US20130172244A1 (en) *	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP2015519309A (ja)	2012-04-16	2015-07-09	カネックファーマインコーポレイテッド	Ｐｔｐ−１ｂインヒビター前駆体としての縮合芳香族ホスホナート誘導体
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
JP6224586B2 (ja)	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
IN2015DN00544A (de)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
EP3395358B1 (de)	2012-09-26	2019-11-06	Indiana University Research and Technology Corporation	Insulinanalogdimere
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6538645B2 (ja)	2013-03-14	2019-07-03	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン‐インクレチン複合物
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
SI3004155T1 (sl)	2013-05-28	2022-02-28	Takeda Pharmaceutical Company Limited	Peptidna spojina
CN103344764B (zh) *	2013-06-19	2014-11-26	天津美德太平洋科技有限公司	胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
EP3057605A1 (de)	2013-10-18	2016-08-24	Novartis AG	Verfahren zur behandlung von diabetes und verwandten erkrankungen
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
CA2929555A1 (en)	2013-11-08	2015-05-14	Baylor Research Institute	Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
US9339482B2 (en)	2013-11-22	2016-05-17	Regents Of The University Of Minnesota	Methods to treat dysregulated blood glucose disorders
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016010599A (es)	2014-02-18	2016-11-18	Novo Nordisk As	Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
EP3110449B1 (de)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medizinische verwendung eines dpp-4-inhibitors
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
PL3129467T3 (pl) *	2014-04-11	2020-05-18	Université Catholique de Louvain	Wysepki od świni transgenicznej i ich zastosowania w leczeniu cukrzycy
CN108271356A (zh)	2014-09-24	2018-07-10	印第安纳大学研究及科技有限公司	肠降血糖素-胰岛素缀合物
JP6701208B2 (ja)	2014-09-24	2020-05-27	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	脂質化アミド系インスリンプロドラッグ
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
CN107108715A (zh)	2014-10-24	2017-08-29	默沙东公司	胰高血糖素和glp‑1受体的共激动剂
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
KR101825048B1 (ko)	2014-12-31	2018-02-05	주식회사 제넥신	GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
PT3257524T (pt)	2015-02-11	2020-11-27	Gmax Biopharm Llc	Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
US10300121B2 (en)	2015-12-21	2019-05-28	Gholam A. Peyman	Early cancer detection and enhanced immunotherapy
US10136820B2 (en)	2015-12-21	2018-11-27	Gholam A. Peyman	Method to visualize very early stage neoplasm or other lesions
US11433260B2 (en)	2015-12-21	2022-09-06	Gholam A. Peyman	Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US11090385B2 (en)	2015-12-21	2021-08-17	Gholam A. Peyman	Early cancer detection and enhanced immunotherapy
US9849092B2 (en)	2015-12-21	2017-12-26	Gholam A. Peyman	Early cancer detection and enhanced immunotherapy
US11660229B2 (en)	2015-12-21	2023-05-30	Gholam A. Peyman	Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US11419543B1 (en)	2016-03-03	2022-08-23	Gholam A. Peyman	Early disease detection and therapy
US10376600B2 (en)	2016-03-03	2019-08-13	Gholam A. Peyman	Early disease detection and therapy
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
JP6995042B2 (ja)	2016-05-24	2022-02-04	武田薬品工業株式会社	ペプチド化合物
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
EP3551651B1 (de)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylierte glp-1/glp-2 duale agoniste
CN107266556A (zh) *	2016-12-14	2017-10-20	江苏师范大学	一种非洲爪蟾胰高血糖素样肽‑1（glp‑1）类似物及其应用
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
WO2019119673A1 (zh)	2017-12-19	2019-06-27	北京吉源生物科技有限公司	一种双基因修饰的干细胞及其用途
CN113181346A (zh) *	2018-03-09	2021-07-30	上海仁会生物制药股份有限公司	用于治疗肥胖和体重管理的glp-1组合物
CN117126279A (zh)	2018-03-20	2023-11-28	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
AR116632A1 (es)	2018-10-11	2021-05-26	Intarcia Therapeutics Inc	Polipéptidos análogos de la amilina humana y sus métodos de uso
EP3938037A1 (de) *	2019-03-15	2022-01-19	Diet4Life ApS	Kombination von diätetischen peptiden
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
GB201917723D0 (en)	2019-12-04	2020-01-15	Nv Rose Llc	Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
EP4085077A4 (de)	2019-12-31	2024-01-17	Beijing QL Biopharmaceutical Co., Ltd.	Fusionsproteine aus glp-1 und gdf15 und konjugate davon
CN113728013B (zh)	2020-01-11	2022-06-14	北京质肽生物医药科技有限公司	Glp-1和fgf21的融合蛋白的缀合物
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
US11998765B2 (en)	2020-09-29	2024-06-04	Cancer Rx, LLC	Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery
CN114729060B (zh)	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
WO2023284822A1 (en)	2021-07-14	2023-01-19	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion polypeptides for metabolic disorders
EP4323413A4 (de)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	Flüssige pharmazeutische zusammensetzungen aus polypeptidkonjugaten und verfahren zur verwendung davon
CN119744271A (zh)	2022-09-08	2025-04-01	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases
WO2024168253A1 (en)	2023-02-10	2024-08-15	Possible Medicines Llc	Delivery of an rna guided recombination system
WO2024168265A1 (en)	2023-02-10	2024-08-15	Possible Medicines Llc	Aav delivery of rna guided recombination system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK179286D0 (da) *	1986-04-18	1986-04-18	Nordisk Gentofte	Insulinpraeparat
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
WO1993016105A1 (en)	1992-02-07	1993-08-19	Merrell Dow Pharmaceuticals Inc.	Phenylalanine analogs of bombesin
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
EP0969016A2 (de)	1992-06-15	2000-01-05	Scios Inc.	Dem Glukagon ähnliche Peptide und Insulinotropin-Derivate
WO1995005848A1 (en)	1993-08-24	1995-03-02	Novo Nordisk A/S	Protracted glp-1
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
GB9502830D0 (en)	1995-02-14	1995-04-05	Ecole Polytech	Regulation of polypeptide production in cells
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
DE69740176D1 (de)	1996-03-01	2011-05-26	Novo Nordisk As	Appetithemmendes Peptid, Zusammensetzung und Verwendung
ATE493998T1 (de)	1996-08-08	2011-01-15	Amylin Pharmaceuticals Inc	Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US5762953A (en) *	1996-08-22	1998-06-09	Theratech, Inc.	Transdermal propentofylline compositions for the treatment of Alzheimers disease
EP0929576A1 (de)	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivate
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de)	1996-11-12	2005-12-29	Novo Nordisk A/S	Verwendung von glp-1 peptiden

1997
- 1997-04-11 UA UA99063107A patent/UA65549C2/uk unknown
- 1997-10-30 US US08/961,405 patent/US6191102B1/en not_active Expired - Lifetime
- 1997-11-04 AT AT97947357T patent/ATE234112T1/de not_active IP Right Cessation
- 1997-11-04 DE DE69719798T patent/DE69719798T2/de not_active Revoked
- 1997-11-04 HU HU0003314A patent/HUP0003314A3/hu unknown
- 1997-11-04 MY MYPI97005206A patent/MY129220A/en unknown
- 1997-11-04 CN CNB971812322A patent/CN1268391C/zh not_active Expired - Lifetime
- 1997-11-04 EP EP97947357A patent/EP0946191B1/de not_active Revoked
- 1997-11-04 YU YU24199A patent/YU24199A/sh unknown
- 1997-11-04 ES ES97947357T patent/ES2194224T3/es not_active Expired - Lifetime
- 1997-11-04 IL IL129852A patent/IL129852A/en not_active IP Right Cessation
- 1997-11-04 PT PT97947357T patent/PT946191E/pt unknown
- 1997-11-04 CA CA2271169A patent/CA2271169C/en not_active Expired - Lifetime
- 1997-11-04 AU AU52457/98A patent/AU734042B2/en not_active Expired
- 1997-11-04 NZ NZ335995A patent/NZ335995A/en not_active IP Right Cessation
- 1997-11-04 WO PCT/US1997/020114 patent/WO1998019698A1/en not_active Ceased
- 1997-11-04 DK DK97947357T patent/DK0946191T3/da active
1999
- 1999-05-27 NO NO992557A patent/NO992557L/no not_active Application Discontinuation
2000
- 2000-06-01 US US09/585,186 patent/US6583111B1/en not_active Expired - Lifetime
2003
- 2003-05-05 US US10/429,522 patent/US7211557B2/en not_active Expired - Fee Related
2007
- 2007-03-30 US US11/693,877 patent/US20070173452A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040018975A1 (en)	2004-01-29
HUP0003314A3 (en)	2001-12-28
IL129852A0 (en)	2000-02-29
DE69719798D1 (de)	2003-04-17
US7211557B2 (en)	2007-05-01
AU5245798A (en)	1998-05-29
HUP0003314A2 (hu)	2001-02-28
CN1268391C (zh)	2006-08-09
US6583111B1 (en)	2003-06-24
DK0946191T3 (da)	2003-07-14
ES2194224T3 (es)	2003-11-16
US20070173452A1 (en)	2007-07-26
NZ335995A (en)	2001-02-23
NO992557D0 (no)	1999-05-27
US6191102B1 (en)	2001-02-20
EP0946191A1 (de)	1999-10-06
EP0946191B1 (de)	2003-03-12
AU734042B2 (en)	2001-05-31
MY129220A (en)	2007-03-30
YU24199A (sh)	2002-12-10
WO1998019698A1 (en)	1998-05-14
NO992557L (no)	1999-06-15
PT946191E (pt)	2003-06-30
CA2271169A1 (en)	1998-05-14
DE69719798T2 (de)	2004-02-12
UA65549C2 (uk)	2004-04-15
HK1024874A1 (en)	2000-10-27
CA2271169C (en)	2012-09-04
CN1242707A (zh)	2000-01-26
IL129852A (en)	2007-10-31

Legal Events

Date

Code

Title

Description

2003-08-15

UEP

Publication of translation of european patent specification

Ref document number: 0946191

Country of ref document: EP

2006-12-15

RZN

Patent revoked

Publication	Publication Date	Title
ATE234112T1 (de)	2003-03-15	Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
DE69731373D1 (de)	2004-12-02	Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
CY1108610T1 (el)	2014-04-09	Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DK1025124T3 (da)	2008-10-06	Human interferon-alfa-analoge med lav toksicitet
GB0123381D0 (en)	2001-11-21	Factor
AU3441400A (en)	2000-10-16	Peptide
PL342078A1 (en)	2001-05-21	Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
EP0923376A4 (de)	2001-09-26	Behandlung von asthma und atemwegerkrankungen
EP1231218A3 (de)	2002-10-30	Peptid zur Appetitzügelung, dessen Zusammensetzungen und Verwendung
BG100974A (en)	1998-04-30	Vaccines against papillomavirus
DK0960127T3 (da)	2010-03-29	Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IL127366A0 (en)	1999-10-28	Insulin preparations containing NaCl
PT1246835E (pt)	2009-04-15	Sapogeninas substituídas e sua utilização
IL127918A0 (en)	1999-11-30	Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
GB9923076D0 (en)	1999-12-01	Sapogenin derivatives and their use
UA41355C2 (uk)	2001-09-17	Засіб для лікування нейро-сніду
DE69840415D1 (de)	2009-02-12	Haemasterlin analoge
NO983177L (no)	1998-07-10	Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
GB9923078D0 (en)	1999-12-01	Sapogenin derivatives and their use
WO2000078795A3 (en)	2001-07-05	Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
EP1306092A3 (de)	2003-05-07	Periphäre Verabreichung von GLP-1 Analogen und Derivate zur Regulierung der Fettleibigkeit
DE68911509D1 (de)	1994-01-27	26-aminocholesterol und derivate und analoge davon bei der regulierung der cholesterolanhäufung in den körpergefässen.
ATE398134T1 (de)	2008-07-15	Neue analoga von nitrobenzylthioinosin
DE69409961D1 (de)	1998-06-04	Triarylethylenderivate zur therapeutischen verwendung
BG103859A (en)	2000-07-31	The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions